Lanreotide Autogel: a review of its use in the management of acromegaly.

@article{Croxtall2008LanreotideAA,
  title={Lanreotide Autogel: a review of its use in the management of acromegaly.},
  author={Jamie D. Croxtall and Leland J. C. Scott},
  journal={Drugs},
  year={2008},
  volume={68 5},
  pages={
          711-23
        }
}
Lanreotide Autogel (ATG) [Somatuline Depot] is a novel, long-acting preparation of the somatostatin analogue lanreotide acetate that acts via somatostatin receptors to reduce both growth hormone (GH) and insulin-like growth factor-I (IGF-I) levels. It is indicated for the management of acromegaly and, relative to most other licensed agents, it has a favourable pharmacokinetic profile that permits administration once every 28-42 days. Subcutaneous lanreotide ATG was an effective and generally… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 12 CITATIONS

Similar Papers

Loading similar papers…